In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

For patients presenting with moderate to severe pemphigus, the choice of initial therapy has been distilled to a single agent: rituximab. This drug is more rapidly effective, more likely to provide ...

Anti-CD20 B cell-depleting agents such as rituximab may offer a promising initial disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple ...

The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion. Rituxan (rituximab) ...

In a new study, rituximab therapy was found to be an effective treatment option for lupus nephritis (LN) management. After six months of use, people with lupus nephritis taking the therapy showed ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

Rituximab demonstrated superiority to azathioprine in a randomized trial. Recent data continue to support the use of rituximab as the standard of care for maintenance therapy for patients with ...

A 1000 mg ×2 induction regimen followed by maintenance every 6–12 months was associated with near-elimination of relapse activity over 12 months (ARR 2.08 to 0.12). NEDA-3 at 12 months was achieved by ...

All cases of IgG4-ROD were either steroid dependent or steroid resistant. Rituximab doses for induction therapy included two doses of 1000 mg at 2-weekly intervals, and four doses at 375 mg/m 2 at ...

Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition: is ...